Comparative Effectiveness of Intravesical BCG-Tice and BCG-Moreau in Patients With Non–muscle-invasive Bladder Cancer-Reference-Cited by-同舟云学术

Comparative Effectiveness of Intravesical BCG-Tice and BCG-Moreau in Patients With Non–muscle-invasive Bladder Cancer

Published:2020-02 Issue:1 Volume:18 Page:20-25.e2
ISSN:1558-7673
Container-title:Clinical Genitourinary Cancer
language:en
Short-container-title:Clinical Genitourinary Cancer

Author:

D’Andrea David,Soria Francesco,Abufaraj Mohammad^ORCID,Pones Mario,Gontero Paolo,Machado André T.,Waksman Ricardo,Enikeev Dmitry V.,Glybochko Petr V.,Adonias Sanarelly Pires,Nahas William Carlos,Shariat Shahrokh F.,Chade Daher C.

Publisher

Elsevier BV

Subject

Urology,Oncology

Reference28 articles.

1. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer;Malmström;Eur Urol,2009

2. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials;Sylvester;J Urol,2002

3. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016;Babjuk;Eur Urol,2017

4. Bladder cancer in the elderly;Shariat;Urol Oncol,2009

5. Genome plasticity of BCG and impact on vaccine efficacy;Brosch;Proc Natl Acad Sci U S A,2007

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Why is it necessary to produce a BCG strain in Spain?;Actas Urológicas Españolas (English Edition);2024-09

2. ¿Por qué es necesario tener una cepa de BCG fabricada en España?;Actas Urológicas Españolas;2024-09

3. Multi-omics analysis reveals that linoleic acid metabolism is associated with variations of trained immunity induced by distinct BCG strains;Science Advances;2024-04-05

4. Carcinoma In Situ (CIS): Is There a Difference in Efficacy between Various BCG Strains? A Comprehensive Review of the Literature;Cancers;2024-01-05

5. Novel immunotherapeutic options for BCG‐unresponsive high‐risk non‐muscle‐invasive bladder cancer;Cancer Medicine;2023-12